Skip to main content

Table 2 Kidney replacement therapy

From: Extracorporeal adsorption of protective and toxic bile acids and bilirubin in patients with cholestatic liver dysfunction: a prospective study

Reasons for CKRT

 AKI stage 2 (KDIGO)

6 (30)

 AKI stage 3 (KDIGO)

11 (55)

 Hyperkalemia

2 (10)

 Lactate acidosis

1 (5)

Dialyzer

Fresenius MultiFiltrate circuit (MultiFiltrate Ultraflux® AV 1000S)

CVVHD (CiCa®)/CVVHDF (MultiBic®, post-dilution)

15 (75)/5 (25)

 Clotting

2 (13.3)/2 (40)

Blood flow (ml/min)

100 [100, 162]

 CVVHD

100 [100, 100]

 CVVHDF

200 [200, 300]

Dialysate flow (ml/h)

2000 [2000, 2125]

Substitute flow (if CVVHDF) (ml/h)

2000 [1000, 3500]

Anticoagulation

 Citrate

15 (75)

 Unfractioned Heparin < 1000 IE/h

8 (40)

 Unfractioned Heparin > 1000 IE/h

4 (20)

 Agatrobane

5 (25)

 None

3 (15)

  1. CKRT continuous kidney replacement therapy, CVVHD(F) continuous veno-venous hemodialysis/hemodiafiltration